ReviewFrontiers in immunology2023

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer.

Yanping Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.